Cumberland Pharmaceuticals Inc. (CPIX) Current Ratio
- Current ratio · latest quarter: Value 0.96×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.96× | Current assets / current liabilities. $33.64M ÷ $35.19M ≈ 0.96× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 33.64M USD | Assets, Current |
| Current obligations | 35.19M USD | Liabilities, Current |
| Cash and equivalents | 3.86M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 13.42M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 29.93K USD | Inventory, Net |
| Payables | 19.55M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.64M | $35.19M | $3.86M | (m) | $13.42M | $29.93K | $19.55M | (m) | 0.96× |
| 2026-03-31 | $32.79M | $34.49M | $11.01M | (m) | $14.26M | $5.45M | $16.54M | (m) | 0.95× |
| 2025-12-31 | $37.06M | $36.74M | $11.44M | (m) | $16.94M | $29.93K | $18.57M | (m) | 1.01× |
| 2025-09-30 | $29.94M | $24.31M | $15.20M | (m) | $10.43M | $2.93M | $13.83M | (m) | 1.23× |
| 2025-06-30 | $31.21M | $23.97M | $16.09M | (m) | $10.32M | $3.22M | $13.45M | (m) | 1.30× |
| 2025-03-31 | $31.88M | $25.52M | $15.11M | (m) | $10.49M | $4.10M | $13.93M | (m) | 1.25× |
| 2024-12-31 | $36.45M | $31.62M | $17.96M | (m) | $11.70M | $4.00M | $13.91M | $5.10M | 1.15× |
| 2024-09-30 | $35.24M | $31.09M | $17.46M | (m) | $11.31M | $4.51M | $12.06M | (m) | 1.13× |
| 2024-06-30 | $35.58M | $24.76M | $17.34M | (m) | $11.62M | $4.30M | $12.51M | (m) | 1.44× |
| 2024-03-31 | $36.21M | $26.43M | $18.55M | (m) | $10.65M | $4.33M | $13.08M | (m) | 1.37× |
| 2023-12-31 | $35.71M | $27.98M | $18.32M | (m) | $9.76M | $4.61M | $14.04M | $0.00 | 1.28× |
| 2023-09-30 | $41.77M | $27.33M | $18.51M | (m) | $12.62M | $8.67M | $10.82M | (m) | 1.53× |
| 2023-06-30 | $43.67M | $26.96M | $18.25M | (m) | $12.22M | $10.93M | $10.91M | (m) | 1.62× |
| 2023-03-31 | $43.81M | $25.71M | $16.39M | (m) | $14.53M | $10.18M | $11.22M | (m) | 1.70× |
| 2022-12-31 | $45.87M | $28.58M | $19.76M | (m) | $13.16M | $9.86M | $10.82M | (m) | 1.60× |
| 2022-09-30 | $49.16M | $25.31M | $19.54M | (m) | $15.23M | $10.65M | $11.51M | (m) | 1.94× |
| 2022-06-30 | $43.75M | $24.25M | $18.22M | (m) | $13.28M | $9.42M | $10.59M | (m) | 1.80× |
| 2022-03-31 | $45.34M | $24.56M | $17.27M | (m) | $14.64M | $9.88M | $11.45M | (m) | 1.85× |
| 2021-12-31 | $45.69M | $19.28M | $27.04M | (m) | $6.88M | $8.43M | $9.64M | (m) | 2.37× |
| 2021-09-30 | $47.22M | $17.95M | $25.84M | (m) | $9.85M | $10.26M | $9.23M | (m) | 2.63× |
| 2021-06-30 | $46.68M | $18.65M | $25.67M | (m) | $9.15M | $10.10M | $8.96M | (m) | 2.50× |
| 2021-03-31 | $49.38M | $22.85M | $24.92M | (m) | $12.55M | $10.01M | $10.47M | (m) | 2.16× |
| 2020-12-31 | $49.97M | $25.67M | $24.75M | (m) | $12.38M | $10.64M | $13.40M | (m) | 1.95× |
| 2020-09-30 | $48.89M | $23.94M | $26.65M | (m) | $9.66M | $10.08M | $10.83M | (m) | 2.04× |
| 2020-06-30 | $45.75M | $22.66M | $27.37M | (m) | $7.92M | $7.63M | $10.83M | (m) | 2.02× |
| 2020-03-31 | $44.74M | $19.37M | $27.03M | (m) | $5.95M | $8.15M | $8.25M | (m) | 2.31× |
| 2019-12-31 | $50.16M | $24.15M | $28.21M | (m) | $7.86M | $8.87M | $9.99M | (m) | 2.08× |
| 2019-09-30 | $49.40M | $21.05M | $26.98M | (m) | $8.30M | $9.86M | $8.23M | (m) | 2.35× |
| 2019-06-30 | $51.93M | $22.32M | $20.95M | (m) | $8.43M | $10.65M | $9.54M | (m) | 2.33× |
| 2019-03-31 | $57.97M | $28.00M | $24.61M | (m) | $9.97M | $11.26M | $9.29M | (m) | 2.07× |
| 2018-12-31 | $59.12M | $27.80M | $27.94M | $8.29M | $6.46M | $9.78M | $8.21M | (m) | 2.13× |
| 2018-09-30 | $63.63M | $15.52M | $38.26M | (m) | $7.06M | $6.43M | $8.45M | (m) | 4.10× |
| 2018-06-30 | $66.65M | $16.81M | $35.91M | (m) | $5.81M | $7.35M | $10.07M | (m) | 3.96× |
| 2018-03-31 | $66.82M | $16.29M | $35.26M | (m) | $6.30M | $6.66M | $8.52M | (m) | 4.10× |
| 2017-12-31 | $68.68M | $17.69M | $45.41M | $4.67M | $8.40M | $6.74M | $8.98M | (m) | 3.88× |
| 2017-09-30 | $66.08M | $15.80M | $42.02M | (m) | $7.21M | $5.86M | $7.92M | (m) | 4.18× |
| 2017-06-30 | $63.29M | $12.98M | $34.62M | (m) | $6.11M | $5.55M | $6.41M | (m) | 4.88× |
| 2017-03-31 | $63.54M | $14.07M | $34.97M | (m) | $4.93M | $5.65M | $7.27M | (m) | 4.52× |
| 2016-12-31 | $65.55M | $14.79M | $34.51M | $15.62M | $7.33M | $5.37M | $8.04M | (m) | 4.43× |
| 2016-09-30 | $66.96M | $11.69M | $35.55M | (m) | $6.67M | $4.98M | $6.66M | (m) | 5.73× |
| 2016-06-30 | $63.99M | $8.90M | $35.84M | (m) | $4.55M | $4.92M | $3.67M | (m) | 7.19× |
| 2016-03-31 | $64.92M | $11.14M | $36.44M | (m) | $4.82M | $4.07M | $4.07M | (m) | 5.83× |
| 2015-12-31 | $64.58M | $12.41M | $38.20M | $14.56M | $6.08M | $4.27M | $2.88M | (m) | 5.20× |
| 2015-09-30 | $67.72M | $11.87M | $38.32M | (m) | $5.80M | $4.21M | $4.13M | (m) | 5.70× |
| 2015-06-30 | $68.20M | $11.55M | $38.94M | (m) | $5.81M | $4.80M | $4.11M | (m) | 5.91× |
| 2015-03-31 | $67.55M | $11.89M | $39.04M | (m) | $5.17M | $4.63M | $3.37M | (m) | 5.68× |
| 2014-12-31 | $70.81M | $13.75M | $39.87M | $14.84M | $5.50M | $5.60M | $3.24M | (m) | 5.15× |
| 2014-09-30 | $70.15M | $12.16M | $39.64M | (m) | $5.30M | $6.13M | $3.21M | (m) | 5.77× |
| 2014-06-30 | $70.63M | $11.86M | $39.05M | (m) | $6.01M | $7.00M | $4.22M | (m) | 5.95× |
| 2014-03-31 | $69.27M | $11.35M | $39.05M | (m) | $5.42M | $7.42M | $4.72M | (m) | 6.10× |
| 2013-12-31 | $68.68M | $7.55M | $40.87M | $14.02M | $4.53M | $5.72M | $2.04M | (m) | 9.10× |
| 2013-09-30 | $78.27M | $5.41M | $46.01M | (m) | $4.19M | $5.44M | $2.27M | (m) | 14.46× |
| 2013-06-30 | $82.44M | $6.09M | $49.66M | (m) | $3.97M | $6.09M | $3.09M | (m) | 13.53× |
| 2013-03-31 | $86.02M | $8.24M | $51.21M | (m) | $5.97M | $5.99M | $3.43M | (m) | 10.44× |
| 2012-12-31 | $87.23M | $8.06M | $54.35M | $16.69M | $6.02M | $6.22M | $2.79M | (m) | 10.83× |
| 2012-09-30 | $86.79M | $8.66M | $50.80M | (m) | $5.47M | $7.51M | $4.23M | (m) | 10.02× |
| 2012-06-30 | $86.26M | $7.13M | $52.27M | (m) | $4.99M | $7.32M | $2.94M | (m) | 12.09× |
| 2012-03-31 | $86.28M | $6.16M | $55.64M | (m) | $4.46M | $6.01M | $2.30M | (m) | 14.01× |
| 2011-12-31 | $87.31M | $6.60M | $70.60M | $0.00 | $7.08M | $5.77M | $1.51M | (m) | 13.23× |
| 2011-09-30 | $85.88M | $7.45M | $71.07M | (m) | $4.51M | $6.87M | $3.28M | $0.00 | 11.52× |
| 2011-06-30 | $84.34M | $10.73M | $69.83M | (m) | $4.82M | $7.45M | $2.30M | $4.00M | 7.86× |
| 2010-12-31 | $81.04M | $9.23M | $65.89M | (m) | $5.15M | $7.68M | $2.12M | $2.67M | 8.78× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |